...
首页> 外文期刊>American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons >A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.
【24h】

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

机译:在具有高水平供体特异性同种抗体的肾脏同种异体移植受体中血浆置换术与大剂量IVIG脱敏的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Several protocols allow for the successful transplantation of sensitized renal allograft recipients, yet no one best method has emerged. The aim of the current study was to compare the efficacy of high-dose IVIG with two different plasmapheresis (PP)-based regimens in kidney transplant recipients with high levels of donor specific alloantibody (DSA) defined as a positive T-cell cytotoxicity crossmatch. With the primary goal of achieving a negative crossmatch, we employed three protocols sequentially between April 2000 and May 2005: (i) PP, low-dose IVIG, anti-CD20 antibody (n = 32); (ii) high-dose IVIG (n = 13); and (iii) PP, low-dose IVIG, anti-CD20 antibody and pre-transplant Thymoglobulin combined with post-transplant DSA monitoring (n = 16). IVIG decreased DSA activity in all treated patient, yet only 38% (5/13) achieved a negative crossmatch. In contrast, a negative crossmatch was achieved in 84% in PP group and 88% in the PP/monitoring group (p < 0.01 vs. IVIG). Even with a negative crossmatch, the rejection rates were 80% (IVIG), 37% (PP) and 29% (PP/monitoring), respectively, (p < 0.05 IVIG vs. PP). We conclude that multiple PP treatments leads to more reproducible desensitization and lower humoral rejection rates than a single high-dose of IVIG, but that no regimen was completely effective in preventing humoral rejection.
机译:有几种方案可以成功移植致敏的肾同种异体移植受体,但还没有一种最佳方法出现。本研究的目的是比较高剂量IVIG与两种基于血浆置换(PP)的方案在具有高水平供体特异性同种抗体(DSA)定义为阳性T细胞细胞毒性交叉匹配的肾脏移植接受者中的疗效。为了实现负交叉匹配的主要目标,我们在2000年4月至2005年5月之间依次采用了三种协议:(i)PP,低剂量IVIG,抗CD20抗体(n = 32); (ii)大剂量IVIG(n = 13); (iii)PP,低剂量IVIG,抗CD20抗体和移植前胸腺球蛋白与移植后DSA监测相结合(n = 16)。 IVIG在所有接受治疗的患者中均降低了DSA活性,但只有38%(5/13)的交叉配对阴性。相比之下,PP组和PP /监测组的交叉交叉匹配率为84%(负值)(相对于IVIG,p <0.01)。即使交叉匹配为负,拒绝率也分别为80%(IVIG),37%(PP)和29%(PP /监控)(p <0.05 IVIG vs. PP)。我们得出的结论是,与一次高剂量的IVIG相比,多次PP治疗可导致更可再现的脱敏和更低的体液排斥率,但是没有一种方案能够完全有效地预防体液排斥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号